Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hayato Yokota

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Pharmaceutical Health Care and Sciences|May 19, 2026
Delayed decrease in voriconazole concentration after resolution of inflammation in a patient with invasive pulmonary aspergillosis: a case reportHaruka Igarashi, Hayato Yokota, Ayano Saito, et al.
Cureus|May 22, 2025
Efficacy of Switching to Levetiracetam After S-1-Induced Phenytoin Concentration Increase: A Case ReportHayato Yokota, Haruka Igarashi, Yumiko Akamine, et al.
Biology|October 23, 2021
Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung CancerHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Journal of Pharmaceutical Health Care and Sciences|August 14, 2024
Naldemedine-induced perforation of a diverticulum in the sigmoid colon of a patient with opioid-related constipation: a case reportHayato Yokota, Yumiko Akamine, Mizuki Kobayashi, et al.
Journal of Clinical Pharmacy and Therapeutics|May 14, 2020
Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancerHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Clinical Lung Cancer|June 6, 2017
Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung CancerHayato Yokota, Kazuhiro Sato, Yuji Okuda, et al.
Cancer Chemotherapy and Pharmacology|March 29, 2025
Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancerHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2023
Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysisHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Investigational New Drugs|September 23, 2022
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancerHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Case Reports in Oncological Medicine|April 9, 2026
Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non-Small Cell Lung CancerHayato Yokota, Satoshi Goshima, Yuji Okuda, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Pharmaceutical Health Care and Sciences|May 19, 2026
Delayed decrease in voriconazole concentration after resolution of inflammation in a patient with invasive pulmonary aspergillosis: a case reportHaruka Igarashi, Hayato Yokota, Ayano Saito, et al.
Cureus|May 22, 2025
Efficacy of Switching to Levetiracetam After S-1-Induced Phenytoin Concentration Increase: A Case ReportHayato Yokota, Haruka Igarashi, Yumiko Akamine, et al.
Biology|October 23, 2021
Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung CancerHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Journal of Pharmaceutical Health Care and Sciences|August 14, 2024
Naldemedine-induced perforation of a diverticulum in the sigmoid colon of a patient with opioid-related constipation: a case reportHayato Yokota, Yumiko Akamine, Mizuki Kobayashi, et al.
Journal of Clinical Pharmacy and Therapeutics|May 14, 2020
Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancerHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Clinical Lung Cancer|June 6, 2017
Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung CancerHayato Yokota, Kazuhiro Sato, Yuji Okuda, et al.
Cancer Chemotherapy and Pharmacology|March 29, 2025
Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancerHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2023
Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysisHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Investigational New Drugs|September 23, 2022
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancerHayato Yokota, Kazuhiro Sato, Sho Sakamoto, et al.
Case Reports in Oncological Medicine|April 9, 2026
Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non-Small Cell Lung CancerHayato Yokota, Satoshi Goshima, Yuji Okuda, et al.
Pageof 2